SAILIFENSE7 February 2025

Sai Life Sciences Limited has informed the Exchange about Investor Presentation

Sai Life Sciences Limited

Date: 07 February 2025

To National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 NSE Scrip Symbol: SaiLife

To BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400001 BSE Scrip Code: 544306

Sub: Investor Updates for the quarter ended 31 December 2024

Dear Sir/ Madam,

With reference to the above subject, we enclose herewith the Investor Updates for the quarter ended 31 December 2024.

We request you to take note of the same and oblige.

Thank you.

For Sai Life Sciences Limited

____________________________ Runa Karan Company Secretary & Compliance Officer Membership No.: A13721

Encl: As above

Sai Life Sciences Limited

CIN: U24110TG1999PLC030970

Registered Office: Plot No.DS-7, IKP Knowledge Park, Turkapally (V), Shameerpet Mandal, Medchal-Malkajgiri Dist-500078, Telangana, India.

T: +91 40 6815 6000, F: +91 40 6815 6199

E: info@sailife.com www.sailife.com

Corporate Office:

# L4-01&02, SLN Terminus, Survey #133, Gachibowli Miyapur Road, Gachibowli, Hyderabad-500032, Telangana, India.

Sai Life Sciences Limited

Earnings Presentation

February 07, 2025

Message from Managing Director & CEO

“

We are pleased to announce a healthy performance this quarter, driven by strong execution, expanding

capacity, and deepening customer relationships. Our integrated CRDMO model continues to differentiate us

in the market, enabling us to provide seamless solutions across the drug development lifecycle. The

pharmaceutical and biotech industries are increasingly seeking partners with end-to-end capabilities,

scientific excellence, and a commitment to speed and efficiency areas where Sai Life Sciences has built a

strong competitive edge.

The global CRDMO industry presents a tremendous growth opportunity, particularly as large pharmaceutical

Mr. Krishna Kanumuri

MD & CEO

and biotech companies diversify their supply chains and seek strategic partners beyond China. India is at

the forefront of this transformation, with the potential to scale as a global innovation hub. With a robust

pipeline of commercial molecules, a growing presence in key global markets, and continuous investments in

technology and infrastructure, Sai Life Sciences is well-positioned to capitalize on these industry tailwinds.

As we look ahead, we remain focused on strengthening our service offerings, expanding our capabilities

into new modalities, and driving operational excellence. Our unwavering commitment to innovation, quality,

and customer-centricity will continue to propel us forward, delivering sustainable value to all our

stakeholders. “

Message from Chief Financial Officer

“

We are delighted to share our Q3 FY25 financial performance, which highlights robust business momentum,

operational discipline, and strong customer relationships.

Revenue from operations grew to ₹439.8 Cr, up 15% from ₹383.6 Cr in Q3FY24, on account of continued

momentum in both our CDMO and CRO businesses. Our EBITDA margin increased to 28.3% in Q3FY25, up from

27.5% in Q3FY24, reflecting improved operating leverage and enhanced productivity. PAT grew to ₹53.9 Cr,

compared to ₹39.6 Cr in Q3FY24, highlighting that our operational strategies are delivering results and positioning

the company for sustained financial strength.

This success is driven by disciplined cost management despite rising employee costs in line with our ongoing

investment in talent and organizational growth. Finance costs remained relatively stable at ₹23.1 Cr for Q3 FY25,

compared to ₹23.3 Cr in the same quarter last year, indicating effective debt management. As of December 2024,

the Company had repaid ₹585.7 Cr of debt out of the planned ₹720.0 crores from the IPO proceeds. The remaining

debt was repaid in January, and we expect a reduction in interest costs in the following quarter. We remain focused

on investing in digital initiatives, new technologies, and commercial capabilities to fuel future growth.

Over the past five years, our strategic investments in talent, technology, and infrastructure have strengthened our

position as a leading integrated CRDMO player. These investments are now translating into higher customer

retention, an expanding product pipeline, and improving profitability.

Looking ahead, we expect sustained growth momentum, supported by a strong order pipeline and ongoing

Mr. Siva Chittor

CFO

investments in infrastructure and capabilities.

“

Quarter Highlights

Performance Snapshot

Q3FY25

REVENUE

Q3FY25

EBITDA

Q3FY25

PAT

₹ 440 Cr

15%YoY Growth

₹ 124 Cr

19%YoY Growth

₹ 54 Cr

36%YoY Growth

9MFY25

REVENUE

9MFY25

EBITDA

9MFY25

PAT

₹ 1,115 Cr

9% YoY Growth

₹ 264 Cr

50%YoY Growth

₹ 82 Cr

207%YoY Growth

Continued momentum in both CDMO & CRO business

Improved operating leverage and enhanced productivity

PAT Expansion on the back of EBITDA Margin expansion

Key Financial Highlights

Revenue (₹ Cr)

EBITDA (₹ Cr) and Margin (%)

PAT (₹ Cr)

384

396

440

27%

104

109

28%

124

Q3FY24

Q2FY25

Q3FY25

Q3FY24

Q2FY25

Q3FY25

Q3FY24

Q2FY25

Q3FY25

YoY Growth

15%

QoQ Growth

11%

YoY Growth

19%

QoQ Growth

15%

YoY Growth

36%

QoQ Growth

30%

1,026

1,115

24%

264

17%

176

9MFY24

9MFY25

YoY Growth

9MFY24

9MFY25

9MFY24

9MFY25

YoY Growth

50%

YoY Growth

207%

Y L R E T R A U Q

S H T N O M

E N

Operating Highlights: Key Business Updates

CDMO

CRO

60%

9MFY25 Revenue Contribution

40%

• Both CRO and CDMO businesses continue to demonstrate growth momentum, supported by increased business from existing customers and new collaboration

CAPITAL EXPENDITURE

• Capital expenditure for 9MFY25 was ~₹300 Cr

•

The Company has added an additional 100 KL in November to its manufacturing capacity. The Company further expects to add an additional 100 KL in Q1FY26.

The Company has expanded its Discovery R&D capacity in Hyderabad by addition of lab spaces for chemistry by 15%

• Average Capacity Utilization for the 9MFY25 was 65%

STRONG CASH FLOW GENERATION

• Operating cash

flow

for 9MFY25 stood at ₹246 Cr, accounting for 93% of EBITDA for the period. The company also generated a positive free cash flow of ₹21 Cr during this timeframe

Company Overview

Sai Life Sciences at a Glance

25+

Years of experience

(Incorporated in 1999)

One-stop platform for discovery, development and manufacturing

USFDA, PMDA

100% successful track record of

regulatory inspections across our R&D and manufacturing facilities.

Diverse therapy areas Oncology, CNS, Inflammation, Antivirals, Rare diseases and more

3,000+

Total employees

10+

Years: Enduring customer relationships

300+

>65%

20+

Discovery programs completed

Integrated Drug Discovery (IDD)

Assays transferred from Boston to Hyderabad

300+

Active customers across US, UK, EU, Japan

18/25

of the largest pharmaceutical companies are customers

18months

Demonstrated time from Hit to IND

Commercial molecules in current portfolio of projects

Filed / Phase III molecules in current portfolio of projects

Tech Transfers from UK to India

40+

Programs advanced to IND or Phase I/II/III

Molecules from discovery to market

Experienced Management Team and Board Supported by a Qualified Scientific Talent Pool

Experienced Founder and Management Team with Average 25+ Years of Industry Experience

Kanumuri Ranga Raju Chairman and Whole time Director

25+

Krishna Kanumuri Managing Director and Chief Executive Officer

Siva Chittor Chief Financial Officer

15+

Sauri Gudlavalleti Chief Operations Officer

Maneesh Raghunath Pingle

20+

Dean David Edney Senior Vice President & Global Head - Process Research & Development

A Vasanthamurugesh Senior Vice President - Manufacturing and Technology Transfer

10+

Chopperla Srikrishna Senior Vice President & Head of Safety

13+

Sidhartha Das Senior Vice President -

HR and Administration

Executive Vice President & Head – Discovery Services

BVNBS Sarma Senior Vice President & Head - Discovery

Runa Karan Company Secretary, Compliance

Officer and Legal Head

22+

16+

Supported by an

Experienced Board

Mitesh Daga Non-Executive Director

Tuneer Ghosh Executive Vice President & Head – CMC Services

Rajagopal Srirama Tatta Independent Director

10+

Muniandi Damodharan

Chief Quality Officer - Global Quality and Regulatory Affairs

Ramesh Ganesh Iyer Independent Director

Suchita Sharma Independent Director

STRONG TALENT POOL

Years at Sai

2,125 Scientists 1,343 Master's Degree

276 PHDs

8+ years avg. experience for scientists and scientific staff

Key Milestones

Acquired additional facilities to include process R&D capabilities – evolving to serve biotech customers

Launched small- scale biotech manufacturing acquired Prasad Drugs, Bolarum, now known as Unit III

Expanded manufacturing capacity by acquiring a 40KL plant, Merrifield Pharma in Bidar, now known as Unit IV.

Successful FDA inspection of GMP Manufacturing site, Unit IV

Expanded Discovery capabilities with the goal to become an integrated Discovery provider

Year of incorporation Started as a Medicinal Chemistry Services provider to US Biotech

Animal Facility gets AAALAC accreditation

Unit II Expansion: Advancing R&D for Pharma CDMO expanded Process and Analytical R&D facilities in Unit II, advancing its capabilities for large- scale pharma CDMO services

Added 100KL capacity at Unit IV to match foray into pharma

1999

2002

2004

2006

2009

2011

2012

2013

2024

2023

2022

2020

2019

2018

2017

2016

Listed on Indian Stock Exchanges (NSE & BSE)

Opened dedicated HPAPI manufacturing block at Unit IV, Bidar

Partnership with Schrodinger

Added special- purpose Amidites block in Unit IV, Bidar

Opened dedicated Clean Room block in Unit IV, Bidar

Opened new production block (PB-08) at Unit IV with >170KL capacity

Forays into international markets with R&D labs in Manchester, UK, and Greater Boston, USA

Successful USFDA audit at Unit IV, Bidar

Added Biology capabilities becoming a fully integrated Discovery player

Opened new production block (PB-07) at Unit IV, Bidar with >120KL capacity

Successful USFDA audits at Unit II and Unit IV; Successful PMDA audit at Unit IV, Bidar

Sai Life Sciences – A Leading CRDMO with scaled operations across both verticals Sai Life Sciences operates as both a Contract Research Organization (CRO) and a Contract Development & Manufacturing Organization (CDMO), offering an end-to-end platform for global pharmaceutical and biotech companies

C R O

C D M O

DRUG

DISCOVERY

PRECLINICAL &

IND SUPPORT

DRUG

DEVELOPMENT

COMMERCIAL

MANUFACTURING

• Medicinal Chemistry - Hit

• DMPK & Toxicology – ADME

identification, lead optimization, and SAR studies

• Biology & Pharmacology – In vivo studies and biomarker discovery

• Computational Drug Discovery – Molecular simulations and data analytics

profiling, safety & efficacy studies

• Regulatory Support – Preclinical

regulatory documentation, IND filing

• Process Research & Development – Route scouting, process intensification, impurity profiling

• GMP Manufacturing – Clinical trial

materials (Phase I-III), API & finished dosage forms

• Analytical Development & Validation – Method validation, stability studies

• Technology Transfer & Commercial Scale-Up – From lab to large-scale production

• Regulatory Compliance – US FDA,

PMDA-certified facilities

Phase 1

DISCOVERY (CRO)

Phase 2

Phase 3

DEVELOPMENT (CRO & CDMO)

MANUFACTURING (CDMO)

One-Stop Platform for Integrated Drug Discovery and Development, ensuring seamless progress from research to commercial manufacturing

Modern R&D and Manufacturing Infrastructure

Discovery Biology Lab, Greater Boston

Process R&D Laboratory, Manchester

Integrated Discovery and Development Facility, Hyderabad

API Manufacturing Facility, Bidar

• Laboratory equipped for fit-for-purpose

exploratory biology

• Centre of excellence in process chemistry

• Houses advanced cellular and biochemical analysis platforms

• Engaged in advanced process research and development

• 21 scientific staff (2)

• 65 scientific staff (2)

• Fully integrated R&D campus for discovery, process development and manufacturing

• 374 member CMC R&D team (2)

• 922 member Discovery services

R&D team (2)

• Houses multi-purpose

production trains

• Manufactures APIs and advanced intermediates for both clinical and commercial purposes

• Capacity – 525KL(1)

• Scientific Staff – 592(2)

Notes: (1) The company also has a production facility in Bollaram with a capacity of 44 KL, leading to a cumulative capacity of 560+ KL (2) As of March 31, 2024

Long Standing Customer Base

Top 25 Global Pharma Companies(1)

Johnson & Johnson

Viatris

Pfizer

Vertex Pharmaceuticals

Novo Nordisk

Merck

Bayer

AstraZeneca

Astellas Pharma

Amgen

AbbVie

Sanofi

Eli Lilly

CSL

Sandoz

Roche

Boehringer Ingelheim

GlaxoSmithKline

Daiichi SankyÅ

Gilead Sciences

Novartis

Teva

Bristol-Myers Squibb

Merck KGaA

Takeda

Source: Frost & Sullivan Notes: (1) In terms of revenue for the calendar year 2023 (2) In FY2024 (3) As of RHP Date

Serve 18 of 25 top global pharma companies(1)

Serve 280+ Innovator Pharmaceutical Companies and Biotechnology Firms(2)

10+ Average relationship tenure years with Top 10 customers (3)

The CRDMO Market Opportunity

Small Molecules with over 65% contribution(1) dominate the Global Pharma Market

72% of 302 FDA approved drugs in 2018–23 were small molecules NCE (New Chemical Entities)

Increasing Outsourcing Across the Pharma Value Chain

• Global Small Molecule Non-clinical CRO Industry in 2028: US$ 6.7Bn (CAGR 2023-28: 7.8%)

• Global Small Molecule Innovator API CDMO Industry in 2028: US$ 51.3Bn (CAGR 2023-28: 6.8%)

India CRDMO industry to grow faster(2) than APAC CRDMO as well as global CRDMO industry on account of

• China +1 (Across the Western World)

• Biosecure Act (USA)

•

Inflation Reduction Act (USA)

Increasing Preference for Integrated CRDMOs – “One Stop Platform”

Source: Frost & Sullivan Notes: (1) By revenue in 2023 (2) During 2023-2028

Annexure

Consolidated Statement of Profit and Loss

Particulars (₹ crores)

Revenue from operations

Other income

Total income

Expenses

Cost of materials consumed and changes in inventories

Employee benefits expense

Other expenses

Forex exchange (gain)/loss

EBITDA

EBITDA Margin

Finance costs

Depreciation and amortisation expense

Profit before tax

Total Tax expense

Profit after tax

Q3FY25

Q2FY25

Q3FY24

9MFY25

9MFY24

440

444

121

133

(5)

124

28%

396

400

104

135

(6)

109

27%

384

387

107

122

(8)

104

27%

1,115

1,126

298

398

171

(16)

264

24%

101

109

1,026

1,037

322

364

179

(15)

176

17%

FY24

1,465

1,479

446

495

239

(15)

300

20%

119

109

Awards & Recognitions

Excellence in Digitalizing Learning & Development, 2023 by ISTD

Awarded as “Excellent Energy Efficient Unit” at CII’s 24th National Energy Management Awards for the fourth consecutive year

Winner of Gold in Brandon Hall Group’s Excellence in Technology Awards in “Best Advance in Content Authoring Technology” category

AAALAC International full Accederation for the animal house

Ecovadis Silver

Glossary

APIs

Biotechs

Active pharmaceutical ingredients

Biotechnology companies, often referred to as biotech companies, are largely startups in the pharmaceutical sector which typically focus on developing innovative drugs and drug development technologies to address unmet medical needs

Blockbuster End Molecules Blockbusters are drug products with annual sales of over US$1 billion in the Financial Year 2023

CDSCO

CMC / CDMO

CMO

Central Drug Standards Control Organization, India

Chemistry, Manufacturing and Control / Contract Development and Manufacturing Organization

Contract Manufacturing Organization

COFEPRIS Mexico

Federal Commission for the Protection against Sanitary Risk of Mexico

CRDMO

CRO

DMPK

GATT

Contract Research, Development, And Manufacturing Organization

Contract Research Organization

Drug metabolism and pharmacokinetics

General Agreement on Tariffs and Trade

Generic drugs

Refer to pharmaceutical drugs that have the same chemical composition as the original innovator drug and can be sold by companies after the patent on the original drug expires

Innovation Clusters/Hubs

Nine regions identified by Frost and Sullivan including Boston/Cambridge in Massachusetts, Manchester/London/Cambridge in UK, Chicago in Illinois, New Jersey, New York, Paris in France, Switzerland and Japan. In 2022, approximately 57% of global R&D spending were in these nine pharma hubs

Innovator Drugs

Refer to first drugs created containing specific active ingredients and undergo approval or patent process for use

Large Molecule

Have a large molecular weight and made of proteins that are complex in structure compared to small molecule drugs. Costly to manufacture and, at this time, in most cases can only be administered by injection or infusion. Typically manufactured biologically, i.e. extracted from living organisms, but often include certain synthetic chemistry processes

Large Pharma Companies

Pharma companies with revenues > USD 10 billion

Mid Pharma Companies

Pharma companies with revenues in range of USD 500 million to USD 10 billion

NCE

PMDA

Small Molecule

New chemical entities

Pharmaceuticals and Medical Devices Agency, Japan

Organic compound with low molecular weight, small molecule drugs are known for their affordability, ease of administration (largely orally), and broad therapeutic coverage. Typically manufactured using synthetic chemistry processes

Small Pharma Companies

Pharma companies with revenues lower than USD 500 million

TRIPS

USFDA

Trade-Related Aspects of Intellectual Property Rights

United States Food and Drug Administration

Safe Harbor

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or

phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan",

"contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions

may constitute "forward-looking statements", These forward looking statements involve a number of risks, uncertainties and other factors that could

cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not

limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies,

technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company

does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Thank You

For more details please contact:

Investorrelation@sailife.com

L4, SLN Terminus, Gachibowli, Hyderabad 500032, Telangana, India.

← All Transcripts SAILIFE Stock Page →

Sai Life Sciences Limited has informed the Exchange about Investor Presentation

Market Movers